한국학술지인용색인(NRF)
권호기사보기
| 기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
|---|
국회도서관 홈으로
정보검색
소장정보 검색
결과 내 검색
동의어 포함
저자 검색
- 검색종류
| 대표형(전거형, Authority) | 생물정보 | 이형(異形, Variant) | 소속 | 직위 | 직업 | 활동분야 | 주기 | 서지 | |
|---|---|---|---|---|---|---|---|---|---|
| 연구/단체명을 입력해주세요. | |||||||||
관련 키워드 검색
- 대표어
- 외국어
|
|
|
|
|
|
주제별 검색
* 주제를 선택하시면 검색 상세로 이동합니다.
초록보기
Objectives: The purpose of this study is to examine the safety of Korean medicine treatment in patients vaccinated with the AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19/AZD1222).
Methods: We investigated patients at Kyung Hee University Korean Medicine Hospital who were vaccinated with the AstraZeneca COVID-19 vaccine between June 1, 2021 and June 30, 2021. The safety of Korean medicine treatment was evaluated by examining adverse events that occurred within seven days of vaccination, including liver function and kidney function testing, assessment of the severity of adverse events, and examination of causality to vaccines and Korean medicine treatment.
Results: Eleven patients vaccinated with the first dose of the AstraZeneca COVID-19 vaccine were included. A total of 19 adverse events were reported: 15 systemic adverse events, three local adverse events, and one alanine aminotransferase increase. The most commonly reported systemic adverse events were fatigue (4 cases, 36.4%), headache (4 cases, 36.4%), and myalgia (4 cases, 36.4%). All adverse events were rated below moderate (grade 2) in severity. Systemic and local adverse events were evaluated as definitely related to vaccination and unlikely to be related to Korean medicine treatment, while alanine aminotransferase increase was evaluated as unlikely to be related to either the vaccine or Korean medicine treatment. Aspartate transaminase, Blood urea nitrogen, and creatinine were measured within the reference range after vaccination.
Conclusion: Our results suggest that the severity and frequency of adverse events in patients vaccinated with the AstraZeneca COVID-19 vaccine did not increase after Korean medicine treatment.권호기사
참고문헌 (22건) : 자료제공( 네이버학술정보 )
| 번호 | 참고문헌 | 국회도서관 소장유무 |
|---|---|---|
| 1 | Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann Intern Med 2021;174(5):687-90. | 미소장 |
| 2 | World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19vaccine AZD1222 Vaxzevria™, SII COVISHIELDTM). Accessed August 6, 2021, https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-S AGE_recommendation-AZD1222-2021.1 | 미소장 |
| 3 | Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021;397(10269):99-111. | 미소장 |
| 4 | Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)vaccine: a pooled analysis of four randomised trials. The Lancet 2021;397(10277):881-91. | 미소장 |
| 5 | Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 2020;396(10249):467-78. | 미소장 |
| 6 | World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine. Accessed August 6, 2021, https://www.who.int/news/item/07-04-2021-interim-statement-of-the-covid -19-subcommittee-of-the-who-global-advisory-c ommittee-on-vaccine-safety | 미소장 |
| 7 | Peltier E. Denmark says it’s permanently stopping use of the AstraZeneca vaccine. The New York Times. Updated April 14, 2021. Accessed August 6, 2021, https://www.nytimes. com/2021/04/14/world/europe/denmark-astrazeneca-vaccine.html | 미소장 |
| 8 | World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS)following adenovirus vector COVID-19 vaccines. Accessed August 6, 2021, https://www.who.int/news/item/26-07-2021-statement-of-the-who-ga cvs-covid-19-subcommittee-on-gbs | 미소장 |
| 9 | Ang L, Lee HW, Choi JY, Zhang J, Lee MS. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integrative Medicine Research 2020;9(2):100407. | 미소장 |
| 10 | Korea Disease Control and Prevention Agency. Adverse Event Management Guidelines after Coronavirus Disease 19 Vaccination (1-3rd Edition). Accessed August 6, 2021 https://ncv.kdca.go.kr/board.es?mid=a12101000000&bi d=0031#content | 미소장 |
| 11 | Ministry of Food and Drug Safety. Guidelines for evaluating severity of adverse reactions in vaccine clinical trials. Accessed August 6, 2021, https://www.mfds.go.kr/brd/m_1060/view. do?seq=13009&srchFr=&srchTo=&srchWord =&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&comp any_nm=&page=83 | 미소장 |
| 12 | US Food and Drug Administration. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Accessed August 6, 2021, https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/to xicity-grading-scale-healthy-adult-and-adolesce nt-volunteers-enrolled-preventive-vaccine-clinical | 미소장 |
| 13 | World Health Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Accessed August 6, 2021, https://www.who.int/publications/m/item/WHO-causality-assessment | 미소장 |
| 14 | European Medicines Agency. Assessment report COVID-19 vaccine AstraZeneca. Accessed August 6, 2021, https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-r eport_en.pdf | 미소장 |
| 15 | World Health Organization. Background document on the AZD1222 vaccine against COVID-19developed by Oxford University and AstraZeneca. Accessed August 6, 2021, https://www.who.int/publications/i/item/background-document-on-t he-azd1222-vaccine-against-covid-19-developed -by-oxford-university-and-astrazeneca | 미소장 |
| 16 | Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. Journal of Korean Medical Science 2021;36(17):e115. | 미소장 |
| 17 | Nam Dj, Oh MS. Review about the Study of Ssanghwa-tang Published in Korea from 2000to 2019. Journal of Haehwa Medicine 2019;28(2):12-9. | 미소장 |
| 18 | Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology 2019;70(6):1222-61. | 미소장 |
| 19 | Wang D, Liu Y, Zhao W. The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine. Frontiers in Molecular Biosciences 2021;8:655570. | 미소장 |
| 20 | Huang J, Tao G, Liu J, Cai J, Huang Z, Chen JX. Current Prevention of COVID-19: Natural Products and Herbal Medicine. Front Pharmacol 2020;11:588508. | 미소장 |
| 21 | Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K, et al. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine 2012;30(36):5368-72. | 미소장 |
| 22 | European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR -Public assessment report. Updated February 18, 2021. Accessed August 6, 2021, https://www.ema.europa.eu/en/documents/assessment-r eport/vaxzevria-previously-covid-19-vaccine-ast razeneca-epar-public-assessment-report_en.pdf | 미소장 |
MARC 보기
오류 데이터 정정요청
*표시는 필수 입력사항입니다.
알림톡 발송
| 전화번호 |
|---|
개인정보 수정 바로가기
연속간행물 권호 선택
우편복사 안내
- ◾ 도서관을 방문하지 못할 경우 인터넷, 팩스 등으로 자료 복사를 신청하고, 복사물을 우편·팩스 등으로 제공받는 서비스
- ◾ 대상자료: 일반도서, 연속간행물 및 학위논문
- ※ 고서, 고잡지, 훼손될 우려가 있는 자료, 마이크로폼 자료 및 신문 등 제외
- ◾ 신청 책수: 1인 5책 이하(1일 기준)
- ◾ 신청 절차: 자료 검색 → 우편복사 목록담기 → 복사 범위 입력 → 우편복사 주문서 입력 → 접수 및 확인
- ※ 저작권법에 의거하여 부분 복사(전체 페이지 수의 1/3 범위 이내)만 가능
- ◾ 복사 범위 입력 예시: (연속 페이지) 1-30, (부분 페이지) 25, 30-40
| 번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
|---|
도서위치안내(서울관)
도서위치안내: / 서가번호:
0
확인
우편복사 목록담기를 완료하였습니다.
내서재에 담기
새로운 서재
*표시는 필수 입력사항입니다.
저장
저장 되었습니다.